The Technical Analyst
Cardiff Oncology Inc [CRDF]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Cardiff Oncology Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.46% $4.35
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 194.35 mill |
| EPS: | -0.930 |
| P/E: | -4.68 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 44.68 mill |
| Avg Daily Volume: | 1.811 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Neutral | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.68 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.80x |
| Company: PE -4.68 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.118 (-97.28%) $-4.23 |
| Date: 2024-04-20 |
| Expected Trading Range (DAY) |
|---|
|
$ 3.74 - 4.97 ( +/- 14.14%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-07 | Levine James E. | Buy | 205 008 | Stock Options |
| 2024-03-07 | Kabbinavar Fairooz | Buy | 205 008 | Stock Options |
| 2024-03-07 | Smeal Tod | Buy | 205 008 | Stock Options |
| 2024-03-07 | Erlander Mark | Buy | 510 000 | Stock Options |
| 2023-12-19 | Pace Gary W | Buy | 30 000 | Common Stock |
| INSIDER POWER |
|---|
| 81.79 |
| Last 96 transactions |
| Buy: 6 518 913 | Sell: 700 088 |
Forecast:
16:00 - $4.33
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $4.33
Forecast 2: 16:00 - $4.33
Forecast 3: 16:00 - $4.33
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.35 (-0.46% ) |
| Volume | 0.562 mill |
| Avg. Vol. | 1.811 mill |
| % of Avg. Vol | 31.03 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For CRDF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
CRDF
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Last 10 Buy Signals
Latest Press Releases
2024-04-08 16:05:00 - Press Release
Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-line Ras-mutated Mcrc Clinical Study
Ras-mutated mcrc – in ras-mutated mcrc, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – enhanced clinical efficacy signal in bev naÏve patients in phase 1b/2 trial is consistent with results of randomized onsemble trial providing two independent data sets in second-line mcrc validating our strategy to evaluate onvansertib in combination with chemo/bev in ras-mutated first-line mcrc – therapeutic areas outside of ras-mutated mcrc – in ras-wild type mcrc, onvansertib demonstrates antitumor activity in preclinical models as a single agent and in combination with cetuximab, highlighting that onvansertib activity in mcrc can be independent of ras mutational status – – in sclc and ovarian cancer, robust preclinical data underscore onvansertib's activity in combination treatments across multiple tumors – san diego, april 08, 2024 (globe newswire) -- cardiff oncology, inc...
2024-03-06 16:05:00 - Press Release
Cardiff Oncology Announces Upcoming Presentations At The Aacr Annual Meeting 2024
San diego, march 06, 2024 (globe newswire) -- cardiff oncology, inc. (nasdaq: crdf), a clinical-stage biotechnology company leveraging plk1 inhibition to develop novel therapies across a range of cancers, today announced publications of five abstracts that will be presented in a poster session at the american association for cancer research (aacr) annual meeting, taking place from april 5-10, 2024, in san diego, california.
2024-02-29 16:07:00 - Press Release
Cardiff Oncology Reports Fourth Quarter And Full Year 2023 Results And Provides Business Update
- first patient dosed in phase 2 first-line trial in patients with ras-mutated mcrc for new lead program with the support of fda and clinical execution from pfizer ignite -
2024-02-29 16:06:00 - Press Release
Cardiff Oncology Provides Clinical Update On Phase 2 Randomized Second-line Onsemble Trial In Patients With Ras-mutated Mcrc
- new clinical data from second-line randomized onsemble trial provides further evidence of the efficacy of onvansertib in combination with folfiri/bev in bev naÏve ras-mutated mcrc patients -
2024-02-29 16:05:00 - Press Release
Cardiff Oncology Announces First Patient Dosed In Randomized First-line Ras-mutated Metastatic Colorectal Cancer Trial (crdf-004)
- phase 2 trial in patients with ras-mutated mcrc will evaluate onvansertib plus soc versus soc alone in the first-line setting -
Latest News
2024-04-01 09:51:08 - Zacks Investment Research
Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why
Cardiff Oncology (CRDF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
2024-03-21 16:05:01 - InvestorPlace
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $5
You get what you pay for and that includes stocks under $5. Yeah, I might be starting off on a negative foot but here's the deal: most securities that are priced this low are that way for a reason.
2024-03-21 08:56:05 - Zacks Investment Research
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
2024-03-14 09:51:11 - Zacks Investment Research
Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Cardiff Oncology (CRDF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
2024-03-14 09:11:05 - Zacks Investment Research
Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last?
Cardiff Oncology (CRDF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
2024-03-08 19:37:17 - Seeking Alpha
Cardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)
Cardiff Oncology is focused on developing a drug for colorectal cancer and pancreatic cancer, with promising early activity shown in colorectal cancer patients. The company is now focused on moving their drug to the first-line setting and has started a clinical trial to evaluate its efficacy. Cardiff Oncology has a strong financial position with enough funds to operate through Q3 2025, but the success of their drug is heavily dependent on the outcomes of a single trial.
2024-03-06 13:01:16 - Zacks Investment Research
What Makes Cardiff Oncology (CRDF) a Strong Momentum Stock: Buy Now?
Does Cardiff Oncology (CRDF) have what it takes to be a top stock pick for momentum investors? Let's find out.
2024-02-29 20:40:18 - Zacks Investment Research
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.20 per share a year ago.
2024-02-29 20:06:03 - Seeking Alpha
Cardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET
2023-11-02 21:11:03 - Seeking Alpha
Cardiff Oncology, Inc. (CRDF) Q3 2023 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Kiki Patel - IR, Gilmartin Group Mark Erlander - CEO Jamie Levine - CFO Conference Call Participants Mark Frahm - TD Cowen Joe Catanzaro - Piper Sandler Companies Andy Hsieh - William Blair & Company Operator Welcome to the Cardiff Oncology third-quarter 2023 financial results and corporate update conference call. [Operator Instructions].